AFMD - Wutah dodolan YoY (TTM) Affimed

Affimed creates unique innate cell activators to combat tumors. The relative change in rolling year revenue compared to the same period last year demonstrates demand dynamics, where the -54.70 mark characterizes this parameter. Stable interest in the drugs offsets supply sanction risks, while a fully staffed team of clinical research experts ensures the sustainable development of the company's R&D core.

This metric measures revenue dynamics over a rolling year, stripping the fundamental trend of seasonal fluctuations and one-off factors to assess actual market share expansion. By analyzing the trailing twelve months (TTM) growth in operating sales revenue, an investor determines the commercialization pace of Affimed immunotherapy and the demand for its drugs within the solid tumor and lymphoma treatment segments across oncology clinics.